

Tissue Diagnostics Market by Product (Consumables (Antibodies, Reagents, Tissue, Probes), Instrument (Processing System, Scanner)), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) - Global Forecast to 2028

Market Report | 2024-01-08 | 254 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global tissue diagnostics market is projected to reach USD 8.4 billion by 2028 from USD 5.6 billion in 2023, at a CAGR of 8.4% during the forecast period. Market growth is driven by factors such as the rising prevalence of cancer, increasing availability of reimbursements and increasing technological advancements in tissue diagnostics are the major factors driving the growth of the market.

"The Consumables to register the largest share of the tissue diagnostics market, by product."

The global tissue diagnostics market product segment is divided into Consumables and Instruments . In product segment the consumables is expected to account for the largest share of the tissue diagnostics market in 2022. Market growth is largely driven by the rise in government and private funding in life sciences and cancer research, growing R&D expenditure by leading pharma companies. Moreover, the availability of better consumables that offer efficient results and precision in diagnosis attributes to their growing demand, resulting in growth of the segment.

"Immunohistochemistry tissue diagnostics segment to grow at a considerable rate among technology during the forecast period."

The tissue diagnostics market is four technology segments, namely, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology & Workflow, and Special Staining. The Immunohistochemistry technology segment is expected to account for the largest share of the tissue diagnostics market in 2022. The large share of this segment can primarily be attributed to the Rising geriatric population and growing prevalence of cancer diseases diabetes, availability of reimbursements for IHC tests, and adoption of digital pathology are driving the demand for immunohistochemistry products.

"Breast Cancer segment accounted for the largest share in the tissue diagnostics market, by disease."

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The global tissue diagnostics market is segmented into Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-small Cell Lung Cancer, and Other Diseases. The breast cancer segment accounted for a largest share in 2022, primarily due number of factors such as age, family history, reproductive history, the presence of dense breast tissues, a lack of physical activity, alcohol consumption, smoking, radiation exposure coupled with the increasing incidence of breast cancer such as ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and inflammatory breast cancer (IBC), among others.

"Asia Pacific: The fastest-growing region in the tissue diagnostics market."

The global tissue diagnostics market is segmented into four major regions - North America, Europe, the Asia Pacific, and Rest of the World (RoW). The Asia Pacific region is expected to grow at the highest rate in the tissue diagnostics market during the forecast period. The high growth in the region is due to the presence of a large target population, the economic growth in the countries of this region and rising prevalence of cancer in Asian countries.

The break-up of the profile of primary participants in the tissue diagnostics market:

-□By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%

-□By Designation: C-level - 27%, D-level - 18%, and Others - 55%

-□By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, and Rest of the World- 10%

The key players in this market are F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Agilent Technologies Inc. (US), Thermo Fisher Scientific, Inc (US), Abbott (US), Merck KGAA (Germany), SAKURA FINETEK JAPAN CO., LTD (Japan), Abcam Plc. (UK), Becton, Dickinson and Company (BD) (US), Bio SB (US), Biogenix (US), Cell Signaling Technology, Inc (US), Histo-Line Laboratories (Italy), SLEE Medical GMBH (Germany), Cellpath Ltd (UK), Amos scientific Pty Ltd. (Australia), Jinhua YIDI Medical Appliance CO.,LTD (China), MEDITE Medical GmbH (Germany), Diapath S.p.A. (Italy), KONFOONG BIOINFORMATION TECH CO.,LTD (China), Diagnostic BioSystems Inc. (US), 3DHISTECH (Hungary), RWD Life Science Co.,LTD (China), Dakewei Biotechnology co., Ltd (China), Sysmax Corporation (Japan), Enzo Life Sciences, Inc. (US), Biocare Medical, LLC. (US), MILESTONE MEDICAL (US), and Bio-Optica Milano Spa (Italy).

Research Coverage:

This research report categorizes the tissue diagnostics market by product (consumables and instruments), technology (immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology & workflow management, special staining), disease type (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, other disease types), end user (hospitals, research laboratories, pharmaceutical companies, Contract Research Organizations (CROs), and Other End Users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the tissue diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the tissue diagnostics market. This report covers the competitive analysis of upcoming startups in the tissue diagnostics market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall tissue diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

-□Analysis of key drivers (the rising prevalence of cancer, growing healthcare expenditure, growing demand for digital pathology, increasing healthcare expenditure, developing infrastructure for cancer diagnosis, increasing availability of reimbursements, and increasing technological advancements in tissue diagnostics are the major factors driving the growth of the market), restraints (high degree of consolidation, high cost of diagnostic imaging system), opportunities (significant opportunities in BRICS countries, growing demand for personalized medicines, increasing number of clinical trials pertaining to cancer drugs, emerging economics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

to offer significant opportunities to companies), challenges (lack of skilled professionals, availability of refurbished products, stringent regulatory requirements, lack of infrastructure and low awareness in middle and low income countries and lack of standardization) and trends (Increasing number of reagent rental agreements, increasing usage of AI in histopathology) influencing the growth of the tissue diagnostics market

-□Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the tissue diagnostics market.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the tissue diagnostics market across varied regions.

-□Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tissue diagnostics market

-□Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Agilent Technologies (US), Thermo Fisher Scientific Inc. (US), and among others in the tissue diagnostics market strategies.

Table of Contents:

1□INTRODUCTION□	31
1.1□STUDY OBJECTIVES□	31
1.2□MARKET DEFINITION□	31
1.3□INCLUSIONS AND EXCLUSIONS□	32
1.4□MARKET SCOPE□	33
1.4.1□MARKETS COVERED□	33
FIGURE 1□MARKET SEGMENTATION□	33
1.4.2□REGIONS COVERED□	33
1.4.3□YEARS CONSIDERED□	34
1.4.4□CURRENCY CONSIDERED□	34
1.5□STAKEHOLDERS□	34
1.6□SUMMARY OF CHANGES□	35
2□RESEARCH METHODOLOGY□	36
2.1□RESEARCH DATA□	36
FIGURE 2□RESEARCH DESIGN□	36
2.1.1□SECONDARY RESEARCH□	37
2.1.1.1□Key data from secondary sources□	38
2.1.2□PRIMARY RESEARCH□	38
2.1.2.1□Primary sources□	39
2.1.2.2□Key data from primary sources□	39
2.1.2.3□Key industry insights□	41
FIGURE 3□BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS□	41
FIGURE 4□BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION□	42
2.2□MARKET SIZE ESTIMATION□	42
2.2.1□BOTTOM-UP APPROACH□	43
FIGURE 5□REVENUE SHARE ANALYSIS□	43
FIGURE 6□CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS□	44
FIGURE 7□TISSUE DIAGNOSTICS MARKET: TOP-DOWN APPROACH□	45
2.3□MARKET BREAKDOWN AND DATA TRIANGULATION□	46
FIGURE 8□DATA TRIANGULATION METHODOLOGY□	46
2.4□MARKET SHARE ANALYSIS□	47
2.5□STUDY ASSUMPTIONS□	47

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.5.1	MARKET ASSUMPTIONS	47
2.5.2	GROWTH RATE ASSUMPTIONS	47
2.6	RESEARCH LIMITATIONS	48
2.6.1	METHODOLOGY-RELATED LIMITATIONS	48
2.6.2	SCOPE-RELATED LIMITATIONS	48
2.7	RISK ASSESSMENT	48
TABLE 1	RISK ASSESSMENT ANALYSIS	48
2.8	RECESSION IMPACT ANALYSIS	48
3	EXECUTIVE SUMMARY	49
FIGURE 9	TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)	49
FIGURE 10	TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)	50
FIGURE 11	TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD BILLION)	50
FIGURE 12	TISSUE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)	51
FIGURE 13	GEOGRAPHICAL SNAPSHOT OF TISSUE DIAGNOSTICS MARKET	52
4	PREMIUM INSIGHTS	53
4.1	TISSUE DIAGNOSTICS MARKET OVERVIEW	53
FIGURE 14	RISING INCIDENCE OF CANCER AND INFECTIOUS DISEASES TO DRIVE MARKET GROWTH DURING FORECAST PERIOD	53
4.2	NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2022)	54
FIGURE 15	CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022	54
4.3	TISSUE DIAGNOSTICS MARKET: GEOGRAPHICAL SNAPSHOT	54
FIGURE 16	CHINA & INDIA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD	54
4.4	TISSUE DIAGNOSTICS MARKET: REGIONAL MIX	55
FIGURE 17	ASIA PACIFIC REGION IS PROJECTED TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD	55
4.5	TISSUE DIAGNOSTICS MARKET: DEVELOPED COUNTRIES VS. EMERGING ECONOMIES	55
FIGURE 18	EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD	55
5	MARKET OVERVIEW	56
5.1	INTRODUCTION	56
5.2	MARKET DYNAMICS	56
FIGURE 19	TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	56
5.2.1	DRIVERS	57
5.2.1.1	Rising incidence of cancer and infectious diseases	57
TABLE 2	INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)	57
TABLE 3	PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2018 VS. 2020 VS. 2040	58
5.2.1.2	Growing demand for digital pathology	59
5.2.1.3	Increasing healthcare expenditure	60
FIGURE 20	CURRENT HEALTH EXPENDITURE PER CAPITA	60
FIGURE 21	CURRENT HEALTH EXPENDITURE (% OF GDP)	60
5.2.1.4	Growing availability of reimbursements	61
5.2.1.5	Rising establishment of private diagnostics centers	62
5.2.2	RESTRAINTS	62
5.2.2.1	High cost of tissue diagnostic systems	62
5.2.2.2	Stringent regulatory requirements	63
5.2.3	OPPORTUNITIES	63
5.2.3.1	High growth potential of emerging economies	63
FIGURE 22	GROWTH IN CURRENT HEALTHCARE EXPENDITURE IN BRICS COUNTRIES, 2012-2020	64
5.2.3.2	Growing preference for personalized medicines	64
FIGURE 23	PERSONALIZED MEDICINES APPROVED BY FDA (%), 2015-2022	65

5.2.3.3	Increasing number of clinical trials for cancer therapeutics	65
5.2.4	CHALLENGES	66
5.2.4.1	Shortage of skilled professionals	66
5.2.4.2	Availability of refurbished products	66
5.2.4.3	Inadequate standardization for TDx	67
5.2.5	INDUSTRY TRENDS	67
5.2.5.1	Increasing number of reagent rental agreements	67
5.2.5.2	Growing usage of AI in histopathology	68
5.3	VALUE CHAIN ANALYSIS	68
FIGURE 24	VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE	69
5.4	SUPPLY CHAIN ANALYSIS	70
FIGURE 25	DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES	70
5.5	TECHNOLOGY ANALYSIS	71
5.6	PORTER'S FIVE FORCES ANALYSIS	71
5.6.1	THREAT OF NEW ENTRANTS	72
5.6.2	BARGAINING POWER OF BUYERS	72
5.6.3	BARGAINING POWER OF SUPPLIERS	72
5.6.4	THREAT OF SUBSTITUTES	72
5.6.5	INTENSITY OF COMPETITIVE RIVALRY	72
5.7	KEY STAKEHOLDERS AND BUYING CRITERIA	73
5.7.1	KEY STAKEHOLDERS IN BUYING PROCESS	73
FIGURE 26	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USERS	73
TABLE 4	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)	73
5.7.2	BUYING CRITERIA	74
FIGURE 27	KEY BUYING CRITERIA FOR TOP THREE END USERS	74
TABLE 5	KEY BUYING CRITERIA FOR END USERS	74
5.8	REGULATORY LANDSCAPE	74
TABLE 6	INDICATIVE LIST OF REGULATORY AUTHORITIES IN TISSUE DIAGNOSTICS MARKET	74
5.9	PATENT ANALYSIS	77
5.10	KEY CONFERENCES AND EVENTS	78
TABLE 7	LIST OF CONFERENCES & EVENTS (2023?2024)	78
5.11	PRICING ANALYSIS	80
TABLE 8	PRICE RANGE FOR TISSUE DIAGNOSTICS	80
5.12	TRADE ANALYSIS	81
TABLE 9	IMPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL/CHEMICAL ANALYSIS, BY COUNTRY, 2018-2022 (USD MILLION)	81
TABLE 10	EXPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL/CHEMICAL ANALYSIS, BY COUNTRY, 2018-2022 (USD MILLION)	81
5.13	ECOSYSTEM MARKET/MAP	82
TABLE 11	TISSUE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM	82
FIGURE 28	KEY PLAYERS OPERATING IN TISSUE DIAGNOSTICS MARKET	83
5.14	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	83
6	TISSUE DIAGNOSTICS MARKET, BY PRODUCT	84
6.1	INTRODUCTION	85
TABLE 12	TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	85
6.2	CONSUMABLES	85
TABLE 13	TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	86

TABLE 14	TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2021-2028 (USD MILLION)	86
6.2.1	ANTIBODIES	86
6.2.1.1	Rising prevalence of infectious diseases to drive market	86
TABLE 15	TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)	87
6.2.2	KITS	87
6.2.2.1	Optimized sensitivity and versatility to boost demand	87
TABLE 16	TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 2021-2028 (USD MILLION)	88
6.2.3	REAGENTS	88
6.2.3.1	Rising uptake in IHC and FISH procedures to support market growth	88
TABLE 17	TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2021-2028 (USD MILLION)	89
6.2.4	PROBES	89
6.2.4.1	Utilization in fluorescence microscopy applications to boost demand	89
TABLE 18	TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2021-2028 (USD MILLION)	90
6.3	INSTRUMENTS	90
TABLE 19	TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	90
TABLE 20	TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)	91
6.3.1	SLIDE-STAINING SYSTEMS	91
6.3.1.1	Development of high-throughput staining systems to drive market	91
TABLE 21	KEY MANUFACTURERS OF AUTOMATED SLIDE STAINERS	92
TABLE 22	TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2021-2028 (USD MILLION)	92
6.3.2	SCANNERS	93
6.3.2.1	Rising use of multiplexed IHC scanners to drive market	93
TABLE 23	TISSUE DIAGNOSTICS MARKET FOR SCANNERS, BY REGION, 2021-2028 (USD MILLION)	93
6.3.3	TISSUE-PROCESSING SYSTEMS	93
6.3.3.1	Rising need for automation to support market growth	93
TABLE 24	TISSUE DIAGNOSTICS MARKET FOR TISSUE-PROCESSING SYSTEMS, BY REGION, 2021-2028 (USD MILLION)	94
6.3.4	OTHER INSTRUMENTS	94
TABLE 25	TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)	95
7	TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY	96
7.1	INTRODUCTION	97
TABLE 26	TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	97
7.2	IMMUNOHISTOCHEMISTRY	97
7.2.1	RIISING UPTAKE OF IHC KITS FOR DIAGNOSTIC APPLICATIONS TO FUEL MARKET	97
TABLE 27	TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2021-2028 (USD MILLION)	98
7.3	IN SITU HYBRIDIZATION	99
7.3.1	ABILITY TO DETECT SPECIFIC RNA AND DNA SEQUENCES TO BOOST DEMAND	99
TABLE 28	TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)	100
7.4	DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT	100
7.4.1	RIISING NEED FOR ANALYSIS AND SEAMLESS MANAGEMENT TO SUPPORT MARKET GROWTH	100
TABLE 29	TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT, BY REGION, 2021-2028 (USD MILLION)	101
7.5	SPECIAL STAINING	101
7.5.1	UTILIZATION IN CANCER DIAGNOSTICS TO BOOST DEMAND	101
TABLE 30	TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 2021-2028 (USD MILLION)	101
8	TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE	102
8.1	INTRODUCTION	103
TABLE 31	GLOBAL CANCER INCIDENCE, 2020 VS. 2040	103

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 32	TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	104
8.2	BREAST CANCER	104
8.2.1	RIISING UPTAKE OF HER2 TESTS FOR CANCER DIAGNOSIS TO DRIVE MARKET	104
TABLE 33	BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040	105
FIGURE 29	ARTICLES PUBLISHED ON BREAST CANCER TISSUE DIAGNOSTICS, 2011-2021	105
TABLE 34	TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2021-2028 (USD MILLION)	105
8.3	GASTRIC CANCER	106
8.3.1	RIISING INCIDENCE OF GASTROINTESTINAL CANCER TO BOOST DEMAND	106
TABLE 35	COLON CANCER INCIDENCE, BY REGION, 2020 VS. 2040	106
TABLE 36	TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2021-2028 (USD MILLION)	107
8.4	LYMPHOMA	107
8.4.1	RIISING INCIDENCE OF NON-HODGKIN'S LYMPHOMA IN ADULTS TO SUPPORT MARKET GROWTH	107
TABLE 37	HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040	108
TABLE 38	NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040	108
TABLE 39	TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 2021-2028 (USD MILLION)	108
8.5	PROSTATE CANCER	108
8.5.1	RIISING UPTAKE OF ISH TESTS FOR DIAGNOSIS TO FUEL MARKET	108
TABLE 40	PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040	109
TABLE 41	TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2021-2028 (USD MILLION)	109
8.6	NON-SMALL CELL LUNG CANCER	109
8.6.1	GROWING FOCUS ON DEVELOPING COMPANION DIAGNOSTIC TESTS TO DRIVE MARKET	109
TABLE 42	TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2021-2028 (USD MILLION)	110
8.7	OTHER DISEASE TYPES	110
TABLE 43	TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASE TYPES, BY REGION, 2021-2028 (USD MILLION)	111
9	TISSUE DIAGNOSTICS MARKET, BY END USER	112
9.1	INTRODUCTION	113
TABLE 44	TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	113
9.2	HOSPITALS	113
9.2.1	ABILITY TO OFFER ADVANCED EQUIPMENT & INFRASTRUCTURE TO DRIVE MARKET	113
TABLE 45	TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2021-2028 (USD MILLION)	114
9.3	RESEARCH LABORATORIES	114
9.3.1	RIISING DEMAND OF SPECIALTY TESTS TO DRIVE MARKET	114
TABLE 46	TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2021-2028 (USD MILLION)	115
9.4	PHARMACEUTICAL COMPANIES	115
9.4.1	INCREASING R&D ACTIVITIES FOR DISEASE DIAGNOSTICS TO DRIVE MARKET	115
TABLE 47	TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021-2028 (USD MILLION)	115
9.5	CONTRACT RESEARCH ORGANIZATIONS	116
9.5.1	OUTSOURCING OF R&D ACTIVITIES TO SUPPORT MARKET GROWTH	116
TABLE 48	CONTRACT RESEARCH ORGANIZATIONS FOR ONCOLOGY DIAGNOSTICS	116
TABLE 49	TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)	116
9.6	OTHER END USERS	117
TABLE 50	TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)	117
10	TISSUE DIAGNOSTICS MARKET, BY REGION	118
10.1	INTRODUCTION	119
TABLE 51	TISSUE DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)	119
10.2	NORTH AMERICA	119
FIGURE 30	TISSUE DIAGNOSTICS MARKET: NORTH AMERICA SNAPSHOT	120

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 52	NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	121
TABLE 53	NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	121
TABLE 54	NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	121
TABLE 55	NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	122
TABLE 56	NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	122
TABLE 57	NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	123
TABLE 58	NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	123
10.2.1	US	123
10.2.1.1	High healthcare expenditure to drive market	123
TABLE 59	US CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040	124
TABLE 60	US: KEY MACROINDICATORS	124
TABLE 61	LIST OF US FDA-APPROVED PRODUCTS FOR TISSUE DIAGNOSTICS	125
TABLE 62	US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	125
TABLE 63	US: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	126
TABLE 64	US: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	126
TABLE 65	US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	126
TABLE 66	US: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	127
10.2.2	CANADA	127
10.2.2.1	High prevalence of cancer to support market growth	127
TABLE 67	CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040	127
TABLE 68	CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	128
TABLE 69	CANADA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	129
TABLE 70	CANADA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	129
TABLE 71	CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	129
TABLE 72	CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	130
10.2.3	NORTH AMERICA: RECESSION IMPACT	130
10.3	EUROPE	131
TABLE 73	EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	131
TABLE 74	EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	132
TABLE 75	EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	132
TABLE 76	EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	132
TABLE 77	EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	133
TABLE 78	EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	133
TABLE 79	EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	134
10.3.1	GERMANY	134
10.3.1.1	Availability of reimbursements for colorectal cancer screening procedures to support market growth	134
TABLE 80	GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040	134
TABLE 81	GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	135
TABLE 82	GERMANY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	135
TABLE 83	GERMANY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	135
TABLE 84	GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	136
TABLE 85	GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	136
10.3.2	UK	136
10.3.2.1	Rising investments in cancer research to propel market	136
TABLE 86	UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	137
TABLE 87	UK: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	138
TABLE 88	UK: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	138

TABLE 89	UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	138
TABLE 90	UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	139
10.3.3		
FRANCE		
139		
10.3.3.1		
Growing focus on early disease diagnosis to boost demand		
139		
TABLE 91	FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040	139
TABLE 92	FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	140
TABLE 93	FRANCE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	140
TABLE 94	FRANCE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	140
TABLE 95	FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	141
TABLE 96	FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	141
10.3.4		
ITALY		
141		
10.3.4.1		
High incidence of cancer and geriatric population to support market growth		
141		
TABLE 97	ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040	142
TABLE 98	ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	142
TABLE 99	ITALY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	143
TABLE 100	ITALY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	143
TABLE 101	ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	143
TABLE 102	ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	144
10.3.5		
SPAIN		
144		
10.3.5.1		
High incidence of chronic diseases to drive market		
144		
TABLE 103	SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025	144
TABLE 104	SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	145
TABLE 105	SPAIN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	145
TABLE 106	SPAIN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	145
TABLE 107	SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	146
TABLE 108	SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	146
10.3.6		
REST OF EUROPE		
146		
TABLE 109	REST OF EUROPE: CANCER INCIDENCE, 2020 VS. 2025	147
TABLE 110	REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	147
TABLE 111	REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	148
TABLE 112	REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	148
TABLE 113	REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	148
TABLE 114	REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	149
10.3.7		
EUROPE: RECESSION IMPACT		
149		
10.4		
ASIA PACIFIC		
150		
FIGURE 31	TISSUE DIAGNOSTICS MARKET: ASIA PACIFIC SNAPSHOT	151
TABLE 115	ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	151
TABLE 116	ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	152
TABLE 117	ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	152
TABLE 118	ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	152
TABLE 119	ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2021-2028 (USD MILLION)	153
TABLE 120	ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	153
TABLE 121	ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	154
10.4.1		
CHINA		
154		
10.4.1.1		
Rising incidence of chronic & infectious diseases to propel market		
154		
TABLE 122	CANCER INCIDENCE, BY CANCER TYPE (CHINA), 2020 VS. 2025	154
TABLE 123	CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	155

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 124	CHINA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	155
TABLE 125	CHINA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	155
TABLE 126	CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	156
TABLE 127	CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	156
10.4.2	JAPAN	156
10.4.2.1	Development of advanced diagnostic products to fuel market	156
TABLE 128	CANCER INCIDENCE, BY CANCER TYPE (JAPAN), 2020 VS. 2040	156
TABLE 129	JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	157
TABLE 130	JAPAN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	157
TABLE 131	JAPAN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	158
TABLE 132	JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	158
TABLE 133	JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	158
10.4.3	INDIA	159
10.4.3.1	Rising establishment of diagnostic centers to drive market	159
TABLE 134	INDIA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025	159
TABLE 135	INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	160
TABLE 136	INDIA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	160
TABLE 137	INDIA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	160
TABLE 138	INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	161
TABLE 139	INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	161
10.4.4	REST OF ASIA PACIFIC	161
TABLE 140	REST OF ASIA PACIFIC: CANCER INCIDENCE, 2020 VS. 2040	162
TABLE 141	REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	162
TABLE 142	REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	163
TABLE 143	REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	163
TABLE 144	REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	163
TABLE 145	REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	164
10.4.5	ASIA PACIFIC: RECESSION IMPACT	164
10.5	REST OF THE WORLD	164
TABLE 146	REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY REGION, 2021-2028 (USD MILLION)	165
TABLE 147	REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	165
TABLE 148	REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	165
TABLE 149	REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	166
TABLE 150	REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)	166
TABLE 151	REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	167
TABLE 152	REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	167
10.5.1	LATIN AMERICA	167
10.5.1.1	Rising number of cancer screening programs to drive market	167
TABLE 153	LATIN AMERICA: CANCER INCIDENCE, 2020 VS. 2025	168
TABLE 154	LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	168
TABLE 155	LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	169
TABLE 156	LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	169
TABLE 157	LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	169
TABLE 158	LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	170
10.5.2	MIDDLE EAST & AFRICA	170
10.5.2.1	Improvements in healthcare infrastructure to support market growth	170
TABLE 159	CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2025	170

TABLE 160	MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	171
TABLE 161	MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021-2028 (USD MILLION)	171
TABLE 162	MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021-2028 (USD MILLION)	172
TABLE 163	MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)	172
TABLE 164	MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)	173
10.5.3	REST OF THE WORLD: RECESSION IMPACT	173
11	COMPETITIVE LANDSCAPE	174
11.1	OVERVIEW	174
11.2	KEY PLAYER STRATEGIES	174
11.2.1	OVERVIEW OF STRATEGIES ADOPTED BY MARKET PLAYERS	174
TABLE 165	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET	175
11.3	REVENUE ANALYSIS OF TOP MARKET PLAYERS	176
FIGURE 32	REVENUE ANALYSIS OF KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET	176
11.4	MARKET SHARE ANALYSIS	177
TABLE 166	TISSUE DIAGNOSTICS MARKET: INTENSITY OF COMPETITIVE RIVALRY	177
FIGURE 33	TISSUE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)	178
11.5	COMPANY EVALUATION MATRIX	179
11.5.1	STARS	179
11.5.2	EMERGING LEADERS	179
11.5.3	PERVASIVE PLAYERS	179
11.5.4	PARTICIPANTS	179
FIGURE 34	TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX	180
11.5.5	COMPETITIVE BENCHMARKING OF KEY PLAYERS	181
TABLE 167	COMPANY FOOTPRINT	181
11.5.6	PRODUCT FOOTPRINT	182
11.5.7	REGIONAL FOOTPRINT	183
11.6	START-UP/SME EVALUATION MATRIX	184
11.6.1	PROGRESSIVE COMPANIES	184
11.6.2	RESPONSIVE COMPANIES	184
11.6.3	DYNAMIC COMPANIES	184
11.6.4	STARTING BLOCKS	184
FIGURE 35	TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES	185
11.7	COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS	186
TABLE 168	TISSUE DIAGNOSTICS MARKET: KEY STARTUPS/SMES	186
11.8	COMPETITIVE SCENARIOS AND TRENDS	187
11.8.1	PRODUCT LAUNCHES & APPROVALS	187
TABLE 169	TISSUE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020?OCTOBER 2023)	187
11.8.2	DEALS	188
TABLE 170	TISSUE DIAGNOSTICS MARKET: DEALS (JANUARY 2020?OCTOBER 2023)	188
11.8.3	OTHER DEVELOPMENTS	189
TABLE 171	TISSUE DIAGNOSTIC MARKET: OTHER DEVELOPMENTS (JANUARY 2020?OCTOBER 2023)	189
12	COMPANY PROFILES	190
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *		
12.1	KEY PLAYERS	190
12.1.1	F. HOFFMANN-LA ROCHE LTD.	190
TABLE 172	F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW	190

FIGURE 36	F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)	191
12.1.2	DANAHER CORPORATION	197
TABLE 173	DANAHER CORPORATION: BUSINESS OVERVIEW	197
FIGURE 37	DANAHER CORPORATION: COMPANY SNAPSHOT (2022)	198
12.1.3	PHC HOLDINGS CORPORATION	202
TABLE 174	PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW	202
FIGURE 38	PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)	203
12.1.4	THERMO FISHER SCIENTIFIC INC.	206
TABLE 175	THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW	206
FIGURE 39	THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)	207
12.1.5	ABBOTT	210
TABLE 176	ABBOTT: BUSINESS OVERVIEW	210
FIGURE 40	ABBOTT: COMPANY SNAPSHOT (2022)	211
12.1.6	AGILENT TECHNOLOGIES, INC.	213
TABLE 177	AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW	213
FIGURE 41	AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2022)	214
12.1.7	MERCK KGAA	218
TABLE 178	MERCK KGAA: BUSINESS OVERVIEW	218
FIGURE 42	MERCK KGAA: COMPANY SNAPSHOT (2022)	219
12.1.8	SAKURA FINETEK JAPAN CO., LTD.	221
TABLE 179	SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW	221
12.1.9	ABCAM PLC	224
TABLE 180	ABCAM PLC.: BUSINESS OVERVIEW	224
FIGURE 43	ABCAM PLC. COMPANY SNAPSHOT (2022)	225
12.1.10	BECTON, DICKINSON AND COMPANY (BD)	227
TABLE 181	BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW	227
FIGURE 44	BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)	228
12.1.11	BIO SB	229
TABLE 182	BIO SB: BUSINESS OVERVIEW	229
12.1.12	BIOGENEX	230
TABLE 183	BIOGENEX: BUSINESS OVERVIEW	230
12.1.13	CELL SIGNALING TECHNOLOGY, INC.	232
TABLE 184	CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW	232
12.1.14	HISTO-LINE LABORATORIES	233
TABLE 185	HISTO-LINE LABORATORIES: BUSINESS OVERVIEW	233
12.1.15	SLEE MEDICAL GMBH	236
TABLE 186	SLEE MEDICAL GMBH: BUSINESS OVERVIEW	236
12.1.16	CELLPATH LTD.	238
TABLE 187	CELLPATH LTD.: BUSINESS OVERVIEW	238
12.2	OTHER PLAYERS	239
12.2.1	AMOS SCIENTIFIC PTY LTD.	239
12.2.2	JINHUA YIDI MEDICAL APPLIANCE CO., LTD.	240
12.2.3	MEDITE MEDICAL GMBH	241
12.2.4	DIAPATH S.P.A.	242
12.2.5	KFBIO KONFOONG BIOINFORMATION TECH CO., LTD	243
12.2.6	DIAGNOSTIC BIOSYSTEMS INC.	244
12.2.7	3DHISTECH LTD.	245

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.2.8 RWD LIFE SCIENCE CO., LTD. 246

12.2.9 DAKWE 247

12.2.10 SYSMEX CORPORATION 248

12.2.11 ENZO LIFE SCIENCES, INC. 249

12.2.12 BIOCARE MEDICAL, LLC. 250

12.2.13 MILESTONE MEDICAL 251

12.2.14 BIO-OPTICA MILANO SPA 252

*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

13 APPENDIX 253

13.1 DISCUSSION GUIDE 253

13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 257

13.3 CUSTOMIZATION OPTIONS 259

13.4 RELATED REPORTS 259

13.5 AUTHOR DETAILS 261

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Tissue Diagnostics Market by Product (Consumables (Antibodies, Reagents, Tissue, Probes), Instrument (Processing System, Scanner)), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) - Global Forecast to 2028

Market Report | 2024-01-08 | 254 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature